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A recent individual patient data meta-analysis showed that antidepressant medication is slightly more efficacious than cognitive behavioral 
therapy (CBT) in reducing overall depression severity in patients with a DSM-defined depressive disorder. We used an update of that dataset, 
based on seventeen randomized clinical trials, to examine the comparative efficacy of antidepressant medication vs. CBT in more detail by 
focusing on individual depressive symptoms as assessed with the 17-item Hamilton Rating Scale for Depression. Five symptoms (i.e., “depressed 
mood” , “feelings of guilt” , “suicidal thoughts” , “psychic anxiety” and “general somatic symptoms”) showed larger improvements in the medica-
tion compared to the CBT condition (effect sizes ranging from .13 to .16), whereas no differences were found for the twelve other symptoms. In 
addition, network estimation techniques revealed that all effects, except that on “depressed mood” , were direct and could not be explained by 
any of the other direct or indirect treatment effects. Exploratory analyses showed that information about the symptom-specific efficacy could help 
in identifying those patients who, based on their pre-treatment symptomatology, are likely to benefit more from antidepressant medication than 
from CBT (effect size of .30) versus those for whom both treatments are likely to be equally efficacious. Overall, our symptom-oriented approach 
results in a more thorough evaluation of the efficacy of antidepressant medication over CBT and shows potential in “precision psychiatry” .
Key words: Depression, antidepressant medication, cognitive behavioral therapy, depressive symptoms, depressed mood, feelings of guilt, 
suicidal thoughts, psychic anxiety, general somatic symptoms, precision psychiatry
(World Psychiatry 2019;18:183–191)
Previous studies have consistently shown that both antide-
pressant medication and cognitive behavioral therapy (CBT) 
are effective acute phase treatments for depression1-3. Con-
ventional meta-analyses indicated that their efficacy is com-
parable4, while a recent individual patient data meta-analysis 
(IPDMA) showed that antidepressant medication is slightly 
more efficacious than CBT5.
IPDMA is a relatively new technique in the field of men-
tal health, that has the advantage to use raw data rather than 
pooling outcomes as in conventional meta-analyses6. This re-
sults in higher statistical power and provides the opportunity 
to not only detect relatively small treatment effects but also to 
assess treatment efficacy in more detail.
Randomized clinical trials (RCTs) on the comparative effi-
cacy of antidepressant medication vs. CBT have primarily fo-
cused on changes in overall depression severity, and related 
outcomes such as response and remission rates. Scales for 
assessing depression severity are often multifactorial7-10, and 
some RCTs have shown that these subscales differ in their re-
sponse to antidepressant medication vs. CBT7-9.
Fried et al10 reported, however, that the multifactorial struc-
ture of several commonly used depression scales is not stable 
over time and, consequently, scale or subscale scores may be 
inappropriate as outcome measures. It would therefore be 
valuable to use data of an IPDMA, with its substantial statisti-
cal power, to assess the comparative efficacy of antidepressant 
medication vs. CBT in more detail; namely, by focusing on in-
dividual symptoms11-13.
An additional advantage of a focus on individual symptoms 
is that it could help in generating hypotheses regarding the dif-
ferential working mechanisms of treatment. Our group was 
the first to apply network estimation techniques in research 
on treatment efficacy, reporting that adjunctive antidepres-
sant medication, relative to psychotherapy alone, was directly 
related to larger improvements in five specific symptoms (i.e., 
direct treatment effects), which were subsequently related 
to larger improvements in two other symptoms (i.e., indirect 
treatment effects)13. Adjunctive medication had no effects, nei-
ther directly nor indirectly, on nine other symptoms. As net-
work estimation techniques can identify the complex patterns 
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in which symptom improvements are related, they have great 
potential in shedding light on the processes taking place dur-
ing treatment.
A detailed assessment of the symptom-specific comparative 
efficacy of antidepressant medication vs. CBT would be im-
portant, as it could inform clinicians more precisely about the 
preferred treatment option for depressed patients in general. 
This is especially valuable as symptoms differ in their clinical 
relevance; for example, an effect on “suicidal thoughts” would 
be more relevant than an effect on “loss of weight”.
The findings might also help in identifying patients who, 
based on their pre-treatment symptomatology, would benefit 
the most from one treatment relative to the other. That is, pa-
tients primarily suffering from symptoms that are affected by 
one treatment would probably benefit more from that treat-
ment than patients primarily suffering from other symptoms. 
A focus on individual symptoms may therefore also be an im-
portant step in “precision psychiatry”.
To our knowledge, this is the first IPDMA that focused on in-
dividual symptoms in a more detailed assessment of the com-
parative efficacy of antidepressant medication vs. CBT in the 
treatment of depression. In a second step, we used network es-
timation techniques to test whether the identified effects were 
direct or indirect. Thirdly, we wanted to explore whether infor-
mation about the symptom-specific effects of antidepressant 
medication vs. CBT could help in identifying patients who, 
based on their pre-treatment symptomatology, are likely to 
benefit more from one treatment relative to the other.
METHODS
Sample
Our starting point was a recent IPDMA including data of 
individual patients who participated in RCTs directly compar-
ing antidepressant medication vs. CBT5. Only studies includ-
ing outpatients with a primary diagnosis of a DSM-II, DSM-III 
or DSM-IV depressive disorder (major depressive disorder or 
dysthymia), as established by a standardized diagnostic inter-
view, were included. In addition, CBT was required to be man-
ualized and use cognitive restructuring as the main treatment 
component. Studies focusing on remitted patients or including 
patients younger than 18 years were excluded. Studies enroll-
ing patients with comorbid general medical disorders were not 
excluded, and no language restrictions were applied.
Twenty-four studies were identified for the IPDMA. Au-
thors were invited via email to provide original data from their 
trial. If the authors did not respond to the request after one 
month, a reminder email was sent and efforts to contact co-
authors were made. Authors of four studies were unreachable 
and authors of another four studies no longer had access to 
the data. Of the remaining sixteen studies, fourteen14-27 used 
the Hamilton Depression Rating Scale (HAM-D) to assess de-
pressive symptoms and were included in the current analyses 
(responsible for 1,472 patients). Three studies28-30 were added 
(responsible for 384 patients) as an update of the dataset.
Of the 1,856 included patients, 843 (45.4%) were randomly 
assigned to CBT and 1,013 (54.6%) to antidepressant medica-
tion (i.e., several studies had double-sized medication condi-
tions). In total, 1,513 (81.5%) had complete pre-treatment data 
on all individual depressive symptoms, with no difference be-
tween antidepressant medication and CBT (82.0% versus 80.9%, 
p=0.53). Of the patients with complete pre-treatment data, 1,070 
(70.7%) had complete post-treatment data on all individual 
items and comprised the sample for our analyses. Slightly more 
patients had incomplete post-treatment data in the medication 
relative to the CBT condition (31.4% versus 26.7%, p=0.04).
Assessment of depressive symptomatology
Individual depressive symptoms were assessed by separate 
items of the 17-item HAM-D31, both before and after treat-
ment (i.e., 8-20 weeks after the pre-treatment assessment). 
The HAM-D includes seventeen items, which are scored from 
0 to 4 (items 1-3, 7-11,15-16) or 0 to 2 (items 4-6, 12-14, 17). 
We chose the HAM-D for the assessment of individual depres-
sive symptoms, as this was the most often used instrument in 
studies on the comparative efficacy of antidepressants vs. CBT. 
Overall depression severity was calculated by the sum of all 
HAM-D items.
Statistical analyses
All non-network analyses were performed using SPSS (ver-
sion 24). First, baseline characteristics were compared be-
tween patients in the medication vs. CBT condition using Χ2 
statistics for categorical variables (i.e., gender and recruit-
ment setting) and independent samples t-tests for continu-
ous variables (i.e., age, timing of post-treatment assessment, 
overall depression severity and individual depressive symp-
tom scores). Then, paired t-tests were performed to compare 
post- treatment to pre-treatment symptom scores for medica-
tion and CBT separately. Independent samples t-tests were 
performed to determine whether change scores of individual 
symptoms differed between the two treatment conditions.
As a sensitivity analysis, we repeated the above tests in a 
dataset (N=1,513) in which change scores of patients with 
missing post-treatment symptom scores were imputed using 
multiple imputation with baseline symptom scores and socio- 
demographics as predictor variables.
In a next step, statistical software R (version 3.3.3) was used 
to estimate a network including treatment condition (medica-
tion vs. CBT) and changes in individual depressive symptoms. 
As this combines a dichotomous variable (treatment condi-
tion) with continuous variables (change scores), the network 
was estimated with package mgm32 using a mixed graphical 
model. This package uses the glmnet package33 to fit penal-
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ized generalized linear models to perform neighborhood se-
lection34. Package qgraph35 was used to visualize the network.
In this network, a direct connection between treatment 
condition and a change in a particular symptom indicates a 
direct symptom-specific effect, which is independent of the 
symptom-specific effects on other symptoms. If treatment 
condition is connected to a particular symptom via one or 
more changes in other symptoms, it may be interpreted as an 
indirect symptom-specific effect.
As a sensitivity analysis, we estimated networks including 
changes in individual symptoms for antidepressant medica-
tion and CBT separately. The package network comparison 
test36 was used to test whether the networks differed.
Lastly, we explored whether it was possible to identify those 
patients who are likely to benefit more from one treatment rela-
tive to the other. We expected that patients primarily suffering 
from symptoms that were affected by one treatment would 
benefit more from that treatment than patients primarily suf-
fering from other symptoms. To test this, two specific severity 
measures were calculated, based on the simple sum of scores 
on those pre-treatment symptoms that: a) were significantly 
impacted by one treatment relative to the other; and b) were the 
least impacted by one treatment condition relative to the other. 
We expected that the effect of treatment condition on overall 
depression severity would be larger in patients with higher 
scores on the first specific severity measure, but not in patients 
with higher scores on the second specific severity measure.
RESULTS
Baseline characteristics
Of the 1,070 included patients, 500 received CBT and 570 
received antidepressant medication. Patients in the two condi-
tions did not differ in any of the socio-demographic and study 
characteristics, except for recruitment setting. In addition, no 
significant differences were found with respect to baseline 
overall depression severity or any of the individual depressive 
symptoms (see Table 1).
Symptom-specific comparative efficacy of antidepressant 
medication vs. CBT
Although overall depression severity improved significantly 
in both treatment conditions (both p<0.001), this improvement 
was slightly but significantly larger for antidepressant medica-
tion than for CBT (Cohen’s d=.15) (see Table 2). All individual 
symptoms also showed significant improvements in both con-
ditions (all p values ≤0.01 for CBT and ≤0.04 for antidepressant 
medication), but significant differences between the two con-
ditions were found only for the symptoms “depressed mood”, 
“feelings of guilt”, “suicidal thoughts”, “psychic anxiety” and 
“general somatic symptoms”. These symptoms showed larger 
improvements for medication than for CBT,  although effect 
sizes were small (Cohen’s d ranging from .13 to .16). No sig-
nificant effects of treatment condition were found for the other 
twelve symptoms.
The results of the sensitivity analysis based on the imputed 
dataset were similar; p values differed somewhat, but improve-
ments between conditions remained comparable.
Direct and indirect symptom-specific effects of 
antidepressant medication vs. CBT
To provide more information about the direct and indirect 
symptom-specific effects of antidepressant medication vs. CBT, a 
network was estimated including treatment condition and chang-
es in individual symptoms (Figure 1). The previously identified 
symptom-specific effects on “feelings of guilt”, “suicidal thoughts”, 
“psychic anxiety” and “general somatic symptoms” were, at least 
partly, direct, indicating that the larger improvements for anti-
depressants relative to CBT could not be fully explained by any 
of the other direct or indirect symptom-specific effects.
The previously identified symptom-specific effect on “de-
pressed mood” was fully indirect, suggesting that improve-
ments in the four symptoms that were directly affected by 
medication relative to CBT resulted, both directly and indi-
rectly, in a larger improvement in “depressed mood”.
Sensitivity analyses showed that the two networks including 
changes in all seventeen individual symptoms did not differ 
for antidepressant medication vs. CBT (p=0.77 for global con-
nectivity, and Holm-Bonferroni corrected p values all ≥0.95 for 
individual connections).
Identifying patients who benefit more from 
antidepressant medication relative to CBT
Lastly, we explored whether it was possible to identify pa-
tients, based on their pre-treatment symptomatology, who 
would benefit more from antidepressant medication than 
from CBT. A specific pre-treatment severity measure was cal-
culated based on the five symptoms that were significantly 
affected by medication over CBT. As expected, only those pa-
tients with the highest scores on this measure improved sig-
nificantly more from antidepressants than from CBT (Cohen’s 
d=.30, see Figure 2).
As a comparison, another specific severity measure was cal-
culated based on the five symptoms that responded the least 
to antidepressant medication relative to CBT (i.e., “agitation”, 
“somatic anxiety”, “genital symptoms”, “loss of weight”, and 
“insight”; all non-significant effects), which was only weakly 
correlated with the first severity measure (r=.23). As expected, 
patients with the highest scores on this measure did not show 
significantly larger improvements for antidepressant medica-
tion relative to CBT, but, interestingly, patients with the lowest 
scores did (Cohen’s d=.33, see Figure 3).
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DISCUSSION
Principal findings
To our knowledge, this study is the first IPDMA that consid-
ered individual depressive symptoms in the comparison of the ef-
ficacy of antidepressant medication vs. CBT. Five symptoms (i.e., 
“depressed mood”, “feelings of guilt”, “suicidal thoughts”, “psychic 
anxiety” and “general somatic symptoms”) showed larger im-
provements in the medication relative to CBT condition, whereas 
no differences were found for the twelve other symptoms. Net-
work estimation techniques revealed that all effects were direct, 
except for the indirect effect on “depressed mood”. Our findings 
further suggest that information about the symptom-specific ef-
ficacy could help in identifying those patients, based on their pre-
treatment symptomatology, who are likely to benefit more from 
antidepressant medication than from CBT.
Symptom-specific efficacy of antidepressant medication 
vs. CBT
Weitz et al5 recently demonstrated that antidepressant medi-
cation was slightly more efficacious in improving overall depres-
sion severity than CBT. This conclusion was not only confirmed 
by our updated IPDMA, but also extended by providing detailed 
information about the symptom-specific efficacy. As the effect 
on overall depression severity was small (effect size of .15), it is 
not surprising that the five identified symptom-specific effects 
were also small (effect sizes ranging from .13 to .16).
Small effects are, however, not uncommon in studies on 
the comparative efficacy of treatments. Given the robustness 
of the findings as well as the clinical relevance of the identi-
fied symptom-specific effects (especially the effect on “suicidal 
thoughts”), we believe that it would be unwise to ignore the 
beneficial effects of antidepressant medication over CBT.







Gender (% female) 67.0 68.8 0.53
Age at baseline (years, mean±SD) 39.8±12.7 40.0±12.6 0.85




Timing of  post-treatment assessment (weeks, mean±SD) 13.2±3.1 13.3±3.1 0.44
Overall depression severity (HAM-D total score, mean±SD) 18.6±4.8 18.3±4.5 0.30
HAM-D scores for individual symptoms (mean±SD)
Depressed mood 2.2±0.8 2.2±0.8 0.64
Feelings of  guilt 1.6±0.9 1.6±0.9 0.25
Suicidal thoughts 0.8±1.0 0.7±0.9 0.14
Early night insomnia 1.0±0.9 1.0±0.9 0.36
Middle night insomnia 1.1±0.8 1.1±0.8 0.57
Early morning insomnia 0.8±0.8 0.7±0.8 0.34
Work and activities 2.4±0.9 2.3±0.9 0.15
Retardation 0.5±0.7 0.6±0.7 0.38
Agitation 0.7±0.9 0.7±1.0 0.22
Psychic anxiety 1.7±0.9 1.7±0.9 0.65
Somatic anxiety 1.6±0.9 1.6±0.9 0.73
Gastrointestinal symptoms 0.6±0.7 0.5±0.7 0.18
General somatic symptoms 1.4±0.6 1.5±0.6 0.38
Genital symptoms 1.2±0.8 1.1±0.8 0.31
Hypochondriasis 0.6±0.8 0.7±0.8 0.16
Loss of  weight 0.3±0.6 0.3±0.6 0.26
Insight 0.1±0.4 0.1±0.3 0.33
ADM – antidepressant medication, CBT – cognitive behavioral therapy, HAM-D – Hamilton Depression Rating Scale
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To our knowledge, no previous RCTs have examined a broad 
spectrum of individual depressive symptoms in comparing the 
efficacy of antidepressant medication vs. CBT, but some have 
considered subscales based on combinations of symptoms7-9. 
None of these studies have found differences in the efficacy on 
cognitive and affective symptoms7-9, although two identified 
short-term effects that disappeared at a later stage7-8.
An explanation for the identified symptom-specific effects 
in our study could lie in the use of IPDMA, which, with its sub-
stantial statistical power, makes it possible to detect relatively 
small effects. In addition, the strategy of combining symptoms 
into subscale scores may have obscured differential responses 
at the level of individual symptoms. Fournier et al9 found, for 
example, no differences between cognitive therapy and anti-
depressants on the “mood” subscale, which incorporates both 
symptoms that did (i.e., “depressed mood”) and did not (i.e., 
“work and activities” and “retardation”) differ between treat-
ment conditions in our study. This combination of findings un-
derlines the importance of sufficient statistical power as well 
as a focus on individual symptoms in research on treatment 
efficacy.
Although Fournier et al did not find any differences in sub-
scales of cognitive and affective symptoms, they did find that 
cognitive therapy was more efficacious than medication in 
improving atypical-vegetative symptoms9. Additional analyses 
showed that this effect was only present for hypersomnia, but 
not increased appetite. It is important to note that these two 
atypical-vegetative symptoms are not included in the 17- item 
HAM-D and, thus, are not considered as outcomes in our study.
We believe that it would be important for future studies to 
also consider atypical-vegetative symptoms as well as other 
clinically relevant symptomatology (e.g., anxiety symptoms 
or alcohol problems). In addition, it would be interesting to 
consider other outcomes that are clinically relevant, such as 
various aspects of quality of life or daily functioning, in order 
to provide a more thorough evaluation of treatment options.
Direct and indirect symptom-specific effects of 
antidepressant medication vs. CBT
Our study used network estimation techniques to shed light 
on the mechanisms of change during treatment. These analy-
ses revealed that four of the five symptom-specific effects were 
direct (i.e., “feelings of guilt”, “suicidal thoughts”, “psychic anxi-
ety” and “general somatic symptoms”) and, thus, were inde-
pendent of any of the other direct or indirect symptom-specific 
effects of antidepressant medication over CBT. The effect on 
“depressed mood” was indirect, indicating that the larger im-
provement was only present in patients who also experienced 
larger improvements in other symptoms in the medication 
relative to CBT condition. It is, however, important to note that 









Overall depression severity (HAM-D total score, mean±SD) 10.49±6.84 9.43±6.87 0.01 .15
HAM-D scores for individual symptoms (mean±SD)
Depressed mood 1.43±1.11 1.28±1.19 0.03 .13
Feelings of  guilt 0.99±1.14 0.82±1.05 0.02 .16
Suicidal thoughts 0.60±1.04 0.44±0.97 0.007 .16
Early night insomnia 0.52±0.95 0.49±1.00 0.56 .03
Middle night insomnia 0.50±1.02 0.45±0.95 0.39 .05
Early morning insomnia 0.38±0.98 0.29±0.96 0.13 .09
Work and activities 1.53±1.29 1.39±1.33 0.08 .11
Retardation 0.40±0.67 0.36±0.76 0.32 .06
Agitation 0.35±0.97 0.37±0.97 0.68 –.02
Psychic anxiety 1.00±1.09 0.85±1.17 0.03 .13
Somatic anxiety 0.68±1.10 0.69±1.16 0.88 –.01
Gastrointestinal symptoms 0.32±0.78 0.29±0.71 0.47 .04
General somatic symptoms 0.75±0.92 0.64±0.83 0.05 .13
Genital symptoms 0.55±0.94 0.57±0.98 0.77 –.02
Hypochondriasis 0.29±0.84 0.32±0.94 0.67 –.03
Loss of  weight 0.15±0.69 0.15±0.66 0.91 –.00
Insight 0.04±0.40 0.04±0.40 0.78 –.00
ADM – antidepressant medication, CBT – cognitive behavioral therapy, HAM-D – Hamilton Depression Rating Scale
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network estimations employ regularization techniques which 
set weak connections to zero and, thus, conservatively identify 
the most relevant connections. This implies that, in reality, an-
tidepressant medication may have a weak direct effect on “de-
pressed mood” and, thus, this effect would not be fully indirect. 
The same might be true for other connections in the network. 
Network estimations are, therefore, not intended to formally 
test for mediation, but do provide insights into the patterns in 
which symptom improvements are related and can be used in 
generating hypotheses.
The network further revealed that improvements in symp-
toms were related in very complex patterns, with connections 
that were often intuitively plausible. It is, for example, easy 
to imagine that patients reporting less depressed mood after 
treatment often also reported fewer problems with work and 
activities, whereas patients reporting fewer gastrointestinal 
symptoms often reported less loss of weight. Interestingly, 
the networks were similar for the two treatment conditions, 
indicating that, regardless of the treatment, patients tend to 
report the same simultaneous symptom improvements. The 
only difference between the treatment conditions, thus, lies in 
the magnitude of improvement of the five symptoms that were 
specifically affected by antidepressant medication over CBT.
Although our findings demonstrate potential in generat-
ing hypotheses regarding the mechanisms of change during 
treatment, it is important to remark that changes in symptoms 
were assessed simultaneously and, consequently, the tempo-
ral relationships between them remain unknown. To examine 
the actual dynamics of symptoms over time, it would be more 
appropriate to use experience sampling method data, includ-
ing multiple assessments with short time intervals37. For such 
research, it would be valuable to also consider other clinically 
Figure 1 Direct and indirect symptom-specific effects of antidepressant medication (ADM) vs. cognitive behavioral therapy (CBT). Treatment 
type is represented by the square (TR), and individual symptoms as circles. Black lines indicate direct connections between treatment condition 
and improvements in individual symptoms (i.e., direct treatment effects), whereas grey lines indicate connections between improvements in 
individual symptoms (i.e., potential indirect treatment effects). Thicker lines represent stronger connections. Darker circles represent stronger 
effects of ADM over CBT. The network is presented at γ=0.25.
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relevant outcomes, as well as factors that are hypothesized to 
play a role in the working mechanisms of treatment, such as 
therapeutic alliance or social support.
Identifying patients who benefit more from 
antidepressant medication relative to CBT
Our findings showed that, in general, antidepressant medi-
cation was more efficacious than CBT in improving “depressed 
mood”, “feelings of guilt”, “suicidal thoughts”, “psychic anxiety”, 
and “general somatic symptoms” (effect sizes ranging from 
.13 to .16). This suggests that patients primarily suffering from 
these five symptoms would benefit more from antidepressant 
medication than from CBT, which was supported by our ex-
ploratory analyses. Only patients with the highest scores on 
these five symptoms showed significantly and substantially 
larger improvements in overall depression severity after medi-
cation relative to CBT (effect size of .30). In contrast, antide-
pressants and CBT were equally efficacious for patients with 
lower scores on these symptoms. Our findings, thus, may be 
an important step in “precision psychiatry”, as they can inform 
clinicians more precisely about the preferred treatment option 



























Figure 2 Stratification based on increasing scores on a specific pre-treatment severity indicator calculated by summing the five symptoms that 



























Figure 3 Stratification based on increasing scores on a specific pre-treatment severity indicator calculated by summing the five symptoms that 
responded the least to antidepressant medication (ADM) relative to cognitive behavioral therapy (CBT). * Cohen’s d=.33.
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Strengths and limitations
Strengths of the current study were that we used data from 
an updated IPDMA, which enabled us to assess treatment ef-
ficacy in more detail by focusing on individual symptoms. Al-
though several studies have used network analysis techniques 
to examine the relations between depressive symptoms at a 
single time point38-41, we were the first to use these techniques 
on changes in symptoms over time in order to distinguish di-
rect and indirect treatment effects13.
However, a focus on symptoms also brings challenges. For 
example, some studies have shown that the inter-rater reliabil-
ity of several HAM-D items was poor42, whereas others were 
more positive43. Therefore, more research is needed on the reli-
ability and validity of assessing individual symptoms, especially 
as a measure of treatment efficacy. In addition, the number of 
response categories on the HAM-D differs across symptoms. 
Sensitivity to detect changes in symptom severity may be high-
er for symptoms with more response categories and this could 
explain the fact that, in general, the largest symptom-specific 
effects in our study, as well as in the study of Hieronymus et al12, 
were observed for symptoms with more response categories.
The HAM-D items comprise a relatively narrow scope of 
possible outcomes and, therefore, it would be valuable to also 
consider other outcomes that are clinically relevant. It would 
also be interesting to consider other treatment options and to 
differentiate between antidepressant medication types, which 
are known to have different side effects44.
CONCLUSIONS
Our study showed that antidepressant medication was more 
efficacious than CBT in improving five, but not twelve other, 
depressive symptoms. Although the five symptom-specific ef-
fects were small (effect sizes of .13 to .16), the specific symp-
toms, such as “suicidal thoughts”, were all clinically relevant 
and, therefore, it would be unwise to ignore them. In addition, 
exploratory analyses suggested that this information could be 
helpful in “precision psychiatry”: based on the pre-treatment 
symptomatology of patients, it was possible to identify those 
who were likely to benefit more from antidepressant medica-
tion than from CBT (effect size of .30) and those for whom both 
treatments were equally efficacious.
We think that such a symptom-oriented approach will be a 
step forward in research on treatment efficacy and we strongly 
encourage other researchers to adopt this approach in studies 
on other treatment options and/or to consider other outcomes.
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